FDA approves Gilead HIV pill Bixlenvo designed to simplify treatment

Key Points:

• The FDA approved Gilead's once-daily HIV pill, Bixlenvo, designed for patients with suppressed virus who struggle with complex treatment regimens or want a new treatment option.
• Bixlenvo combines bictegravir and lenacapavir, making it the first single-tablet regimen for adults unable to use existing one-pill treatments, addressing about 5% of U.S. HIV patients.
• Clinical trials showed Bixlenvo maintains viral suppression comparable to prior regimens, with common side effects including headache, nausea, and diarrhea, and it is generally well tolerated.
• The drug offers a simplified treatment for aging patients with long treatment histories and drug resistance, reducing pill burden and improving quality of life.
• Gilead aims to expand HIV treatment choices around lenacapavir, including daily pills and long-acting injectables, to provide personalized options and combat drug resistance.